We are live on ! Find out more
CNTA

Centessa Pharmaceuticals

Delisted

CNTA was delisted on the 23rd of June, 2026.

80 hedge funds and large institutions have $781M invested in Centessa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $119K | Put options by funds: $27K

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

16% more funds holding

Funds holding: 6980 (+11)

0.33% more ownership

Funds ownership: 76.2%76.53% (+0.33%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

7% less capital invested

Capital invested by funds: $841M → $781M (-$59.5M)

Holders
80
Holders Change
+11
Holders Change %
+15.94%
% of All Funds
1.15%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
17
Increased
27
Reduced
19
Closed
6
Calls
$119K
Puts
$27K
Net Calls
+$92K
Net Calls Change
-$47K
Name Holding Trade Value Shares
Change
Change in
Stake
MVM
1
Medicxi Ventures Management
Jersey
$180M
GA
2
General Atlantic
New York
$87.4M
EC
3
EcoR1 Capital
California
$51.6M +$907K +95,625 +2%
FLAM
4
First Light Asset Management
Minnesota
$43.2M +$16.9M +1,778,515 +59%
PA
5
Perceptive Advisors
New York
$35.5M +$8.06M +850,000 +28%
VVA
6
Vida Ventures Advisors
Massachusetts
$35.5M
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$31.9M +$5.43M +572,294 +19%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$28.2M +$8.3M +875,000 +39%
TCM
9
TCG Crossover Management
California
$26.1M +$8.06M +850,000 +42%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$25.2M
OCA
11
Octagon Capital Advisors
New York
$21.2M +$2.7M +284,975 +14%
AG
12
Artal Group
Luxembourg
$19.1M +$6.64M +700,000 +50%
DCM
13
Driehaus Capital Management
Illinois
$18.9M +$9.37M +987,997 +89%
Morgan Stanley
14
Morgan Stanley
New York
$18.5M -$825K -86,973 -4%
FCM
15
Farallon Capital Management
California
$18M +$15.4M +1,625,000 +438%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$15.9M -$4.7M -495,714 -22%
CAM
17
Cormorant Asset Management
Massachusetts
$14.6M +$9.96M +1,050,000 +187%
5VM
18
5AM Venture Management
California
$11.2M
Franklin Resources
19
Franklin Resources
California
$10.4M
AAA
20
Affinity Asset Advisors
New York
$10.3M +$2.89M +305,156 +37%
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
$9.24M +$7.29M +768,676 +302%
American Century Companies
22
American Century Companies
Missouri
$8.44M +$114K +12,031 +1%
T. Rowe Price Investment Management
23
T. Rowe Price Investment Management
Maryland
$7.53M +$7.91M +833,993 New
TWM
24
Tanager Wealth Management
United Kingdom
$6.29M
PHS
25
PFM Health Sciences
California
$5.74M +$3.04M +320,969 +102%

CNTA Hedge Fund Activity: Q2 2024 in Review

80 of the 6,928 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2024, worth a combined $781M — down 7.1% from $841M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CNTA positions and 6 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $16.9M. The largest seller was Point72 Asset Management, cutting an estimated $4.7M.

  • 80 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2024, up from 69 in Q1 2024.
  • Funds reported $781M of Centessa Pharmaceuticals stock for Q2 2024, down 7.1% quarter-over-quarter.
  • 17 funds opened new Centessa Pharmaceuticals positions in Q2 2024 and 6 closed out, a net change of +11 holders.
  • The largest Centessa Pharmaceuticals buyer in Q2 2024 was First Light Asset Management, an estimated $16.9M added.
  • The largest Centessa Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $4.7M sold.

Based on aggregated 13F filings for Q2 2024.